PHEAST THERAPEUTICS
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California.
PHEAST THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.pheast.com
Total Employee:
11+
Status:
Active
Total Funding:
76 M USD
Current Advisors List
Board_member
Investors List
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Pheast Therapeutics
Catalio Capital Management
Catalio Capital Management investment in Series A - Pheast Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Pheast Therapeutics
Risk & Reward Group
Risk & Reward Group investment in Series A - Pheast Therapeutics
Official Site Inspections
http://www.pheast.com Semrush global rank: 4.45 M Semrush visits lastest month: 2.46 K
- Host name: 104.21.80.1
- IP address: 104.21.80.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pheast Therapeutics"
Company - Pheast
At Pheast, Ivy is the Head of Human Resources, where she is a thought partner to leadership, focused on building working relationships, supporting culture and cultivating a growth mindset …See details»
Home - Pheast
Apr 14, 2025 Pheast’s proprietary discovery platform uncovers “don’t eat me” signals in different cancers to create novel, tumor-specific, macrophage-targeted immunotherapies. We are developing clinical biomarker strategies to advance …See details»
Pheast Therapeutics - Crunchbase Company Profile
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight …See details»
Pheast Therapeutics - LinkedIn
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer.See details»
Pheast Company Profile | Management and Employees List
Pheast Profile and History. Founded in 2020 and headquartered in Palo Alto, California, Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint …See details»
Pheast Therapeutics, Inc. - Immuno-oncology | Tiny Tech Fund
Pheast Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company is pioneering a new approach to cancer …See details»
Pheast Therapeutics - Updates, News, Events, Signals & Triggers
Apr 26, 2022 Organization. Pheast Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. News Insight Details. …See details»
Pheast Therapeutics Company Profile - Office Locations ... - Craft
Pheast Therapeutics $76 m in total funding,. See insights on Pheast Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Pheast Therapeutics Inc - Drug pipelines, Patents, Clinical trials ...
Pheast has engineered PHST001 to bind recombinant CD24 and cell surface CD24 with high affinity and specificity and to block Siglec-10 binding. Pheast scientists have demonstrated …See details»
Pheast - VentureRadar
Pheast takes a different approach to cancer immunotherapy by activating an important type of immune cell found in tumors, the macrophage. ... Associated sectors: Biotechnology; Biotech; …See details»
Investors allocate $76M for piece of Pheast's cancer …
Apr 26, 2022 The leadership team of scientists has built a strong foundation for Pheast, Barkal said, noting that including this expertise at the base of an organization can help maximize success, a philosophy ...See details»
Pheast Therapeutics Inc (Pheast Therapeutics Inc) - 药物管线_专 …
May 7, 2025 Pheast has engineered PHST001 to be a best in class antibody designed to induce macrophages to phagocytose cancer cells and initiate a powerful immune response. About …See details»
Pheast Therapeutics - Funding, Financials, Valuation & Investors
Apr 26, 2022 How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Apr 26, 2022: …See details»
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Feb 18, 2025 “The Pheast team thoughtfully engineered PHST001 and has demonstrated robust activity across tumor types and a favorable safety profile in preclinical studies. I look forward to …See details»
Pheast Raises $76M in Series A Funding to Train the Immune …
Apr 26, 2022 Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against …See details»
Pheast Therapeutics - Contacts, Employees, Board Members
Organization. Pheast Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of …See details»
Pheast : GoodLab
Pheast is bringing new hope to patients by harnessing the innate power of the immune system to defy cancer. Their scientific breakthroughs allow macrophages already inside our bodies to …See details»
Pheast - Overview, News & Similar companies | ZoomInfo.com
Who is Pheast. Founded in 2020 and headquartered in Palo Alto, California, Pheast Therapeutics is a cancer immunotherapy company focused on developing novel check point therapies to …See details»
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 ...
PALO ALTO, Calif., May 13, 2024 — Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the first presentation of …See details»
News - Pheast
Nov 6, 2024 Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024 Read Article. November 6, 2024 . GEN: Parallel Platform …See details»